AR087563A1 - Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) - Google Patents
Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)Info
- Publication number
- AR087563A1 AR087563A1 ARP120103008A ARP120103008A AR087563A1 AR 087563 A1 AR087563 A1 AR 087563A1 AR P120103008 A ARP120103008 A AR P120103008A AR P120103008 A ARP120103008 A AR P120103008A AR 087563 A1 AR087563 A1 AR 087563A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- amino
- hydroxy
- halogen
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical class C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 7
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 6
- -1 -C (H) F2 Chemical group 0.000 abstract 5
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract 4
- 229910052796 boron Inorganic materials 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proveen además composiciones farmacéuticas que comprenden estos compuestos, y el uso de estos compuestos en el tratamiento o en la prevención de infecciones virales, tales como las infecciones por el virus de hepatitis C (HCV), y las enfermedades asociadas con esas infecciones. Reivindicación 1: Un compuesto de la fórmula (1), en donde: R se selecciona independientemente a partir del grupo que consiste en halógeno, alquilo C₁₋₆, alcoxilo, -CN, -CF₃, -O-arilo C₆₋₁₀ opcionalmente sustituido por halógeno, y -O-heteroarilo opcionalmente sustituido por halógeno; R¹ es -C(O)OH, -C(O)NHR⁵ o heterociclilo; R² es alquilo C₁₋₆, cicloalquilo C₃₋₆, -C(H)F₂, -CF₃, u -OR⁶; R³ es -S(O)₂R⁷ o -C(O)R⁷; R⁴ es: (a) heteroarilo sustituido con B(R⁸)-(R⁹), XB(R⁸)-(R⁹), OXB(R⁸)-(R⁹), B⁻(R⁸)-(R⁹)-(R¹²), XB(R⁸)-(R⁹)-(R¹²) o Het opcionalmente sustituido con hidroxilo o hidroxi-alquilo; y en donde el heteroarilo está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente a partir del grupo que consiste en halógeno, alcoxilo C₁₋₆, -C(H)F₂, -CF₃, alquilo C₁₋₆, hidroxilo, hidroxi-alquilo, amino-alquilo, -C(O)NH₂, -C(O)OH, -C(O)NHR⁵, -S(O)₂R⁶, -S(O)₂NH₂, -CN, -OCF₃, -OR⁶, -NR¹⁰R¹¹, -NHC(O)R¹⁰, cicloalquilo C₃₋₆, y heterociclilo; (b) arilo C₆₋₁₀ sustituido con B(R⁸)-(R⁹), XB(R⁸)-(R⁹), OXB(R⁸)-(R⁹), B⁻(R⁸)-(R⁹)-(R¹²), XB(R⁸)-(R⁹)-(R¹²) o Het opcionalmente sustituido con hidroxilo o hidroxi-alquilo; y en donde el arilo C₆₋₁₀ está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente a partir del grupo que consiste en halógeno, alcoxilo C₁₋₆, -C(H)F₂, -CF₃, alquilo C₁₋₆, hidroxilo, hidroxi-alquilo, amino-alquilo, -C(O)NH₂, -C(O)OH, -C(O)NHR⁵, -S(O)₂R⁶, -S(O)₂NH₂, -CN, -OCF₃, -OR⁶, -NR¹⁰R¹¹, -NHC(O)R¹⁰, cicloalquilo C₃₋₆, y heterociclilo; o (c) Het opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente a partir del grupo que consiste en halógeno, alcoxilo C₁₋₆, -C(H)F₂, -CF₃, alquilo C₁₋₆, hidroxilo, hidroxialquilo, amino-alquilo, -C(O)NH₂, -C(O)OH, -C(O)NHR⁵, -S(O)₂R⁶, -S(O)₂NH₂, -CN, -OCF₃, -OR⁶, -NR¹⁰R¹¹, -NHC(O)R¹⁰, cicloalquilo C₃₋₆, y heterociclilo; Het es un anillo heterocíclico monocíclico de 5 ó 6 miembros o un sistema de anillos heterocíclico bicíclico de 8 a 11 miembros, cualquier anillo del cual está ya sea saturado, parcialmente saturado o insaturado, el cual puede estar opcionalmente benzo-fusionado si es monocíclico, o el cual puede estar opcionalmente espiro-fusionado, y en donde cada Het consiste en uno o más átomos de carbono, y un átomo de boro y uno o más átomos de oxígeno; un átomo de boro, un átomo de oxígeno, y un átomo de nitrógeno; o un átomo de boro y uno o más átomos de nitrógeno; R⁵ es hidrógeno, alquilo C₁₋₆, hidroxilo, u -OR⁶; R⁶ es alquilo C₁₋₆, o cicloalquilo C₃₋₆; R⁷ es alquilo C₁₋₆, hidroxi-alquilo, o amino-alquilo, R⁸, R⁹, y R¹² son cada uno independientemente hidroxilo, alcoxilo, o amino-alquilo; o R⁸ y R⁹, o R⁸, R⁹ y R¹², junto con el átomo de boro con el que están unidos, forman un anillo de 5 a 14 miembros, comprendiendo este anillo átomos de carbono, y opcionalmente uno o más heteroátomos, los cuales pueden ser N u O; el anillo puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente a partir del grupo que consiste en alquilo C₁₋₆, hidroxi-alquilo, amino-alquilo, amino, oxo, C(O)OH, C(O)OXOR¹³, C(O)N(R¹⁰)-(R¹¹), N(R¹⁰)-(R¹¹), y cicloalquilo C₃₋₆, cada uno de los cuales puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente a partir del grupo que consiste en hidroxilo, amino, halógeno, C(O)OH, C(O)N(R¹⁰)-(R¹¹), y N(R¹⁰)-(R¹¹); R¹⁰ y R¹¹ son cada uno independientemente hidrógeno o alquilo C₁₋₆; R¹³ es alcoxilo; X es alquileno u -O-alquileno, en donde el alquileno está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente a partir del grupo que consiste en halógeno, alcoxilo C₁₋₆, -C(H)F₂, -CF₃, alquilo C₁₋₆, hidroxilo, hidroxi-alquilo, amino-alquilo, -C(O)NH₂, -C(O)OH, -C(O)NHR⁵, -S(O)₂R⁶, -S(O)₂NH₂, -CN, -OCF₃, -OR⁶, -NR¹⁰R¹¹, -NHC(O)R¹⁰ y cicloalquilo C₃₋₆; m es 1, 2, ó 3; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161525440P | 2011-08-19 | 2011-08-19 | |
| US201261650681P | 2012-05-23 | 2012-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087563A1 true AR087563A1 (es) | 2014-04-03 |
Family
ID=47746761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103008A AR087563A1 (es) | 2011-08-19 | 2012-08-16 | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8927593B2 (es) |
| EP (2) | EP3199531A1 (es) |
| JP (2) | JP6367712B2 (es) |
| KR (1) | KR101913800B1 (es) |
| CN (1) | CN103732065B (es) |
| AR (1) | AR087563A1 (es) |
| AU (1) | AU2012299295B2 (es) |
| BR (1) | BR112014002845A2 (es) |
| CA (1) | CA2844086A1 (es) |
| CL (2) | CL2014000393A1 (es) |
| CO (1) | CO6862153A2 (es) |
| CR (1) | CR20140078A (es) |
| CY (1) | CY1118399T1 (es) |
| DK (1) | DK2744332T3 (es) |
| DO (1) | DOP2014000034A (es) |
| EA (1) | EA032841B1 (es) |
| ES (1) | ES2611731T3 (es) |
| HR (1) | HRP20161743T1 (es) |
| HU (1) | HUE030300T2 (es) |
| IL (1) | IL230487B (es) |
| IN (1) | IN2014CN00572A (es) |
| JO (1) | JO3281B1 (es) |
| LT (1) | LT2744332T (es) |
| MA (1) | MA35443B1 (es) |
| ME (1) | ME02588B (es) |
| MX (1) | MX354676B (es) |
| PE (1) | PE20141201A1 (es) |
| PH (1) | PH12014500385A1 (es) |
| PL (1) | PL2744332T3 (es) |
| PT (1) | PT2744332T (es) |
| RS (1) | RS55462B1 (es) |
| SG (1) | SG10201606883QA (es) |
| SI (1) | SI2744332T1 (es) |
| SM (2) | SMT201700028T1 (es) |
| TW (1) | TWI538915B (es) |
| UY (1) | UY34274A (es) |
| WO (1) | WO2013028371A1 (es) |
| ZA (1) | ZA201401020B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101975233B1 (ko) * | 2011-08-17 | 2019-05-07 | 글락소스미스클라인 엘엘씨 | 치료 방법 |
| PH12014500385A1 (en) | 2011-08-19 | 2020-06-22 | Glaxo Group Ltd | Benzofuran compounds for the treatment of hepatitis c virus infections |
| EA201790776A1 (ru) | 2014-11-10 | 2017-11-30 | Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед | Комбинированные композиции длительного действия и способы лечения гепатита с |
| CR20170191A (es) * | 2014-11-10 | 2017-09-29 | Glaxosmithkline Intellectual Property (No 2) Ltd | Composiciones farmacéuticas de acción prolongada para la hepatitis c |
| KR20180006522A (ko) | 2016-07-07 | 2018-01-18 | 삼성디스플레이 주식회사 | 액정 조성물 및 이를 포함하는 액정 표시 장치 |
| WO2018026656A1 (en) * | 2016-08-01 | 2018-02-08 | University Of Pittsburgh -Of The Commonwealth System Of Higher Education | Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles |
| CN110621672A (zh) * | 2017-03-02 | 2019-12-27 | 组装生物科学股份有限公司 | 环状磺酰胺化合物及其使用方法 |
| CN111868063B (zh) * | 2018-01-17 | 2023-08-01 | 葛兰素史克知识产权开发有限公司 | PI4KIIIβ抑制剂 |
| CA3155559A1 (en) * | 2019-10-25 | 2021-04-29 | Sachiko Koike | Novel substituted condensed ring compound |
| CN111026203B (zh) * | 2019-12-02 | 2021-01-26 | 宁波德晶元科技有限公司 | 一种适用于真空热水壶的加热控制方法与系统 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| WO2001002424A2 (en) * | 1999-07-07 | 2001-01-11 | Du Pont Pharmaceuticals Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
| EP2251344B2 (en) | 2001-01-25 | 2024-04-24 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Formulation of boronic acid compounds |
| AU2003290584B2 (en) | 2002-11-01 | 2009-07-16 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases |
| WO2008051244A2 (en) | 2005-12-01 | 2008-05-02 | Wyeth | Anthranilic acid derivatives useful in treating infection with hepatitis c virus |
| PL1988779T3 (pl) | 2006-02-16 | 2015-10-30 | Anacor Pharmaceuticals Inc | Małe cząsteczki zawierające bor jako środki przeciwzapalne |
| WO2007131072A2 (en) * | 2006-05-02 | 2007-11-15 | Anacor Pharmaceuticals, Inc. | Hydrolytically-resistant boron-containing therapeutics and methods of use |
| US20070286822A1 (en) | 2006-06-12 | 2007-12-13 | Anacor Pharmaceuticals Inc. | Compounds for the Treatment of Periodontal Disease |
| JP4827986B2 (ja) | 2007-06-08 | 2011-11-30 | マンカインド コーポレ−ション | ＩＲＥ−１αインヒビター |
| GB0719366D0 (en) * | 2007-10-03 | 2007-11-14 | Smithkline Beecham Corp | Compounds |
| JP2011512341A (ja) | 2008-02-14 | 2011-04-21 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ウイルス性複素環化合物 |
| EP2187893A4 (en) | 2008-03-06 | 2012-02-22 | Anacor Pharmaceuticals Inc | SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS |
| WO2009137500A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 6-substituted benzofuran compounds to treat infection with hepatitis c virus |
| WO2009137493A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 2-substituted benzofuran compounds to treat infection with hepatitis c virus |
| TW201008933A (en) | 2008-08-29 | 2010-03-01 | Hutchison Medipharma Entpr Ltd | Pyrimidine compounds |
| WO2010027975A1 (en) | 2008-09-04 | 2010-03-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| WO2011050284A1 (en) * | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Pyrazolylpyridine antiviral agents |
| TW201138786A (en) | 2010-02-19 | 2011-11-16 | Glaxo Group Ltd | Therapeutic compounds |
| AR080433A1 (es) | 2010-03-02 | 2012-04-11 | Merck Sharp & Dohme | Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen. |
| WO2011106929A1 (en) | 2010-03-02 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus ns5b polymerase |
| WO2011106986A1 (en) | 2010-03-02 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus ns5b polymerase |
| TW201221131A (en) | 2010-11-18 | 2012-06-01 | Glaxo Group Ltd | Compounds |
| WO2012067664A1 (en) | 2010-11-18 | 2012-05-24 | Glaxo Group Limited | Compounds |
| KR101975233B1 (ko) * | 2011-08-17 | 2019-05-07 | 글락소스미스클라인 엘엘씨 | 치료 방법 |
| WO2013025975A1 (en) * | 2011-08-17 | 2013-02-21 | Glaxosmithkline Llc | Combination treatments for hepatitis c |
| PH12014500385A1 (en) | 2011-08-19 | 2020-06-22 | Glaxo Group Ltd | Benzofuran compounds for the treatment of hepatitis c virus infections |
-
2012
- 2012-08-10 PH PH1/2014/500385A patent/PH12014500385A1/en unknown
- 2012-08-10 CN CN201280040219.3A patent/CN103732065B/zh not_active Expired - Fee Related
- 2012-08-10 PT PT128264983T patent/PT2744332T/pt unknown
- 2012-08-10 EP EP16195408.6A patent/EP3199531A1/en not_active Withdrawn
- 2012-08-10 RS RS20161131A patent/RS55462B1/sr unknown
- 2012-08-10 MX MX2014001989A patent/MX354676B/es active IP Right Grant
- 2012-08-10 LT LTEP12826498.3T patent/LT2744332T/lt unknown
- 2012-08-10 SI SI201230826A patent/SI2744332T1/sl unknown
- 2012-08-10 BR BR112014002845A patent/BR112014002845A2/pt not_active Application Discontinuation
- 2012-08-10 SM SM20170028T patent/SMT201700028T1/it unknown
- 2012-08-10 PE PE2014000197A patent/PE20141201A1/es not_active Application Discontinuation
- 2012-08-10 IN IN572CHN2014 patent/IN2014CN00572A/en unknown
- 2012-08-10 PL PL12826498T patent/PL2744332T3/pl unknown
- 2012-08-10 HR HRP20161743TT patent/HRP20161743T1/hr unknown
- 2012-08-10 WO PCT/US2012/050268 patent/WO2013028371A1/en not_active Ceased
- 2012-08-10 EP EP12826498.3A patent/EP2744332B1/en active Active
- 2012-08-10 SG SG10201606883QA patent/SG10201606883QA/en unknown
- 2012-08-10 JP JP2014526090A patent/JP6367712B2/ja not_active Expired - Fee Related
- 2012-08-10 KR KR1020147007196A patent/KR101913800B1/ko not_active Expired - Fee Related
- 2012-08-10 AU AU2012299295A patent/AU2012299295B2/en not_active Ceased
- 2012-08-10 CA CA2844086A patent/CA2844086A1/en not_active Abandoned
- 2012-08-10 US US13/885,500 patent/US8927593B2/en not_active Expired - Fee Related
- 2012-08-10 EA EA201490213A patent/EA032841B1/ru not_active IP Right Cessation
- 2012-08-10 ES ES12826498.3T patent/ES2611731T3/es active Active
- 2012-08-10 HU HUE12826498A patent/HUE030300T2/en unknown
- 2012-08-10 ME MEP-2016-287A patent/ME02588B/me unknown
- 2012-08-10 DK DK12826498.3T patent/DK2744332T3/en active
- 2012-08-16 AR ARP120103008A patent/AR087563A1/es unknown
- 2012-08-16 JO JOP/2012/0233A patent/JO3281B1/ar active
- 2012-08-17 TW TW101130017A patent/TWI538915B/zh not_active IP Right Cessation
- 2012-08-17 UY UY0001034274A patent/UY34274A/es not_active Application Discontinuation
-
2014
- 2014-01-16 IL IL230487A patent/IL230487B/en not_active IP Right Cessation
- 2014-01-23 CO CO14013113A patent/CO6862153A2/es active IP Right Grant
- 2014-02-10 ZA ZA201401020A patent/ZA201401020B/en unknown
- 2014-02-17 CL CL2014000393A patent/CL2014000393A1/es unknown
- 2014-02-18 CR CR20140078A patent/CR20140078A/es unknown
- 2014-02-19 DO DO2014000034A patent/DOP2014000034A/es unknown
- 2014-03-13 MA MA36832A patent/MA35443B1/fr unknown
- 2014-11-20 US US14/548,524 patent/US9682999B2/en not_active Expired - Fee Related
-
2016
- 2016-12-22 JP JP2016249387A patent/JP2017125010A/ja active Pending
- 2016-12-27 CY CY20161101345T patent/CY1118399T1/el unknown
-
2017
- 2017-01-18 SM SM201700028T patent/SMT201700028B/it unknown
- 2017-02-03 CL CL2017000293A patent/CL2017000293A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087563A1 (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) | |
| AR087793A1 (es) | Compuestos de benzofurano sustituido y metodos para el uso de los mismos en el tratamiento de enfermedades virales | |
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| AR112216A1 (es) | Derivados de azaquinolina | |
| AR087791A1 (es) | Derivados de benzofurano con sustitucion heterociclica y metodos para el uso de los mismos en el tratamiento de enfermedades virales | |
| AR113818A2 (es) | Pirazolo-quinazolinas como inhibidores de proteína quinasa | |
| AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR094550A1 (es) | Inhibidores de btk | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR079689A1 (es) | Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias. | |
| AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR099955A1 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR087607A1 (es) | Derivados de piridazinona | |
| AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
| AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
| AR089285A1 (es) | Derivados de betulina | |
| AR087792A1 (es) | Compuestos heterociclicos tetraciclicos y metodos para el uso de los mismos en el tratamiento de enfermedades virales | |
| AR088474A1 (es) | Derivados de alcoholes de 1-fenil-2-piridinilalquilo como inhibidores de la fosfodiesterasa | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |